One in three advanced melanoma patients treated in a study of Bristol-Myers Squibb’s Opdivo, a cancer immunotherapy medication, survived five years or more.
More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb Co.’s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients.
The study followed 107 patients who were enrolled in an early trial of the drug, which was approved for melanoma by the U.S. Food and Drug Administration in 2014. Thirty-four percent of the participants, all of whom had failed on other drugs, were still alive five years after treatment.
“This is a new benchmark for melanoma,” said F. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute, Boston, and an investigator at Harvard Medical School’s Ludwig Center.
Dr. Hodi presented the findings at the annual meeting of the American Association for Cancer Research in New Orleans. The AACR said a National Cancer Institute database shows that the five-year survival rate for patients diagnosed with advanced melanoma between 2005 and 2011 was 16.6%.
Read Full Article: Bristol’s Opdivo Shows Benefits in Cancer Immunotherapy Trial – WSJ